China’s National Development and Reform Commission (NDRC) has launched a probe into drug pricing at 60 domestic and international pharmaceutical companies, as the country expands its healthcare coverage, Financial Times reported. The state-backed Chinese newspaper Securities Daily said the investigation centers on the difference in prices between imported pharmaceuticals in China and other global markets. The investigation includes the Chinese affiliates of Merck (MRK.NYSE, MRK.FRA), GlaxoSmithKline (GSK.NYSE, GSK.LON, GSK.BOM) and Astellas (4503.TYO,YPH.FRA), among others. The announcement follows a similar probe into the price of baby milk powder.